Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034685364> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2034685364 abstract "Erlotinib is used as a standard treatment for recurrent advanced non-small cell lung cancer (NSCLC). Epidermal growth factor receptor (EGFR) mutations in NSCLC have been shown to be a predictive factor of erlotinib, although the relationship between K-ras oncogene (KRAS) mutations and erlotinib resistance is controversial. Recently, in vitro sequence-dependent interactions of erlotinib and docetaxel have been studied on as a novel therapeutic approach against NSCLC. The purpose of the present study was to determine the optimum novel regimen of erlotinib and docetaxel against NSCLC cells which have EGFR mutation (HCC827 cells), KRAS mutation (A549 cells) or both wild-type (NCI-H292 cells). First, we analyzed the effects of in vitro combination for cell proliferation-inhibition using a combination index. In all cell lines, docetaxel followed by erlotinib treatment showed nearly additive effects. On the other hand, erlotinib followed by docetaxel treatment showed remarkable antagonistic interactions. Second, we examined the effect of combinations on the in vitro apoptosis induction. Erlotinib followed by docetaxel treatment reduced apoptosis induction compared with docetaxel alone; in contrast, docetaxel followed by erlotinib treatment had no inhibitory effects on docetaxel-induced apoptosis in any of the cell lines. Finally, an in vivo tumor growth inhibition test was performed using xenograft models. Docetaxel followed by erlotinib administration resulted in significant tumor growth inhibition compared with erlotinib or docetaxel monotherapy in all models. In conclusion, we demonstrated that docetaxel followed by erlotinib therapy was a potentially optimum regimen against NSCLC regardless of the mutation status of EGFR and KRAS." @default.
- W2034685364 created "2016-06-24" @default.
- W2034685364 creator A5090105195 @default.
- W2034685364 date "2010-09-27" @default.
- W2034685364 modified "2023-09-30" @default.
- W2034685364 title "Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS" @default.
- W2034685364 doi "https://doi.org/10.3892/or_00000965" @default.
- W2034685364 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20878103" @default.
- W2034685364 hasPublicationYear "2010" @default.
- W2034685364 type Work @default.
- W2034685364 sameAs 2034685364 @default.
- W2034685364 citedByCount "20" @default.
- W2034685364 countsByYear W20346853642012 @default.
- W2034685364 countsByYear W20346853642014 @default.
- W2034685364 countsByYear W20346853642015 @default.
- W2034685364 countsByYear W20346853642016 @default.
- W2034685364 countsByYear W20346853642017 @default.
- W2034685364 countsByYear W20346853642018 @default.
- W2034685364 countsByYear W20346853642019 @default.
- W2034685364 countsByYear W20346853642020 @default.
- W2034685364 countsByYear W20346853642021 @default.
- W2034685364 crossrefType "journal-article" @default.
- W2034685364 hasAuthorship W2034685364A5090105195 @default.
- W2034685364 hasBestOaLocation W20346853641 @default.
- W2034685364 hasConcept C121608353 @default.
- W2034685364 hasConcept C126322002 @default.
- W2034685364 hasConcept C143998085 @default.
- W2034685364 hasConcept C2776256026 @default.
- W2034685364 hasConcept C2778087573 @default.
- W2034685364 hasConcept C2779438470 @default.
- W2034685364 hasConcept C2781018059 @default.
- W2034685364 hasConcept C2781187634 @default.
- W2034685364 hasConcept C2781190966 @default.
- W2034685364 hasConcept C2909325608 @default.
- W2034685364 hasConcept C29537977 @default.
- W2034685364 hasConcept C502942594 @default.
- W2034685364 hasConcept C526805850 @default.
- W2034685364 hasConcept C71924100 @default.
- W2034685364 hasConcept C98274493 @default.
- W2034685364 hasConceptScore W2034685364C121608353 @default.
- W2034685364 hasConceptScore W2034685364C126322002 @default.
- W2034685364 hasConceptScore W2034685364C143998085 @default.
- W2034685364 hasConceptScore W2034685364C2776256026 @default.
- W2034685364 hasConceptScore W2034685364C2778087573 @default.
- W2034685364 hasConceptScore W2034685364C2779438470 @default.
- W2034685364 hasConceptScore W2034685364C2781018059 @default.
- W2034685364 hasConceptScore W2034685364C2781187634 @default.
- W2034685364 hasConceptScore W2034685364C2781190966 @default.
- W2034685364 hasConceptScore W2034685364C2909325608 @default.
- W2034685364 hasConceptScore W2034685364C29537977 @default.
- W2034685364 hasConceptScore W2034685364C502942594 @default.
- W2034685364 hasConceptScore W2034685364C526805850 @default.
- W2034685364 hasConceptScore W2034685364C71924100 @default.
- W2034685364 hasConceptScore W2034685364C98274493 @default.
- W2034685364 hasIssue "5" @default.
- W2034685364 hasLocation W20346853641 @default.
- W2034685364 hasLocation W20346853642 @default.
- W2034685364 hasOpenAccess W2034685364 @default.
- W2034685364 hasPrimaryLocation W20346853641 @default.
- W2034685364 hasRelatedWork W1667731616 @default.
- W2034685364 hasRelatedWork W1948677875 @default.
- W2034685364 hasRelatedWork W2011019372 @default.
- W2034685364 hasRelatedWork W2027052672 @default.
- W2034685364 hasRelatedWork W2034685364 @default.
- W2034685364 hasRelatedWork W2045163220 @default.
- W2034685364 hasRelatedWork W2163885776 @default.
- W2034685364 hasRelatedWork W2186047679 @default.
- W2034685364 hasRelatedWork W2420841572 @default.
- W2034685364 hasRelatedWork W2735034105 @default.
- W2034685364 hasVolume "24" @default.
- W2034685364 isParatext "false" @default.
- W2034685364 isRetracted "false" @default.
- W2034685364 magId "2034685364" @default.
- W2034685364 workType "article" @default.